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2Abstract
We studied the efficacy of T cell vaccination with CD4+Th1 clones in lupus-prone 
MRL/Mp-Faslpr/lpr (MRL/lpr) mice.  CD4+Th1 clones, dna51 (V8.3) and rnp2 
(V14), which stimulated anti-dsDNA or U1 ribonucleoprotein (U1RNP) antibody (Ab) 
production respectively, were isolated from splenocytes of MRL/lpr mice.  Antinuclear 
Ab kinetics, renal function, renal histology, survival rate, and lymphocyte subpopulations 
in the spleen were monitored after intravenous adoptive transfer of IL-2-stimulated (s-) or 
irradiated (i-) clones to 3 week old female MRL/lpr mice. Anti-idiotypic humoral and T 
cell responses against the transferred autoreactive Th1 clones were determined in parallel.  
Compared with PBS-treated MRL/lpr mice, anti-dsDNA Ab titers, and the activity index 
for lupus nephritis were all decreased in MRL/lpr mice vaccinated with i-dna51 cells, 
whereas survival rate was not improved.  The numbers of CD4+V8.3 T cells in the 
spleen were also significantly decreased in these mice.  Anti-idiotypic Abs recognizing a 
12 amino acid sequence of clone dna51 T cell receptor 
V8.3-complementarity-determining region (CDR) 3 were detected in the MRL/lpr mice 
that received i-dna51 or s-dna51 cells.  These Abs suppressed dna51 cell proliferation, as 
well as cytotoxicity of CD8+T cells against dna51.  The present study suggests that 
vaccination with CD4+Th1 clone, dna51, elicits anti-idiotypic T cell and humoral 
responses against dna51 in MRL/lpr mice, although the immunoregulatory effects on 
lupus may be limited.  
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31. Introduction
Systemic lupus erythematosus (SLE) is a chronic, remitting and relapsing, multisystem 
autoimmune disease that predominantly affects women. Currently, there is substantial 
evidence that the adaptive and innate immune systems both contribute to the development 
of SLE [1, 2].  It is widely accepted that the uncontrolled hyperactivity of autoreactive T 
and B cells and sustained production of anti-nuclear antibodies (Abs) and immune 
complexes (ICs) are involved in the pathogenesis of lupus.  Both anti-dsDNA Abs and 
ICs contribute to lupus nephritis, and recently DNA-containing ICs have been shown to 
trigger Toll-like receptor 9, the receptor for bacterial CpG DNA in B cells and dendritic 
cells [2, 3].  
     T cells play a central role in the complex series of events culminating in systemic 
tissue damage in SLE.  In human lupus nephritis, restricted T cell receptor usage was 
shown in infiltrating T cells, which exhibit evidence of recent activation [4].  Studies in 
SLE patients and lupus-prone animals have characterized lupus T cells as activated 
autoreactive T cells, presenting with abnormalities of T cell signaling and costimulation, 
and regulatory T cell dysfunction [5, 6].  Anti-dsDNA and chromatin Abs are serological 
hallmarks of SLE and their presence is used to help define lupus nephritis.  Such 
disease-associated antinuclear Ab production is confirmed to be oligoclonal, affinity 
matured, high titer, class switched, and MHC class II-restricted, strongly suggesting 
cognate T cell help and T cell-derived cytokine-driven affinity maturation.  Whereas 
lupus B cells are also over-activated, pathogenesis in lupus-prone mice requires 
autoreactive CD4+  T cells that help autoreactive B cells [7-9].  Such autoreactive T 
cells that help B cells produce anti-dsDNA Ab production have been characterized, and 
limited numbers of T cell epitopes defined on the autoantigens [10, 11].  
     It is noteworthy that autoreactive T cells can escape thymic selection and are 
4detectable in the peripheral blood of both SLE patients and healthy individuals [12].  
Therefore, breakdown of peripheral tolerance results in the expansion of autoreactive T 
cells in the periphery and can contribute to the development of autoimmunity in lupus.  
Defects in activation-induced cell death, ineffective control of elimination by regulatory 
cells, and the abnormal activation of antigen presenting cells (APCs) such as dendritic 
cells, are all involved in ensuring the persistence of expanded autoreactive T cells.  
     Taken together, targeting treatment against peripheral autoantigen-specific T cells 
associated with autoantibody stimulation could represent an effective immunotherapeutic 
approach in lupus.  T cell vaccination (TCV) to eliminate specific pathogenic 
autoreactive T cells, for example, by immunization with irradiated autologous T cells in 
multiple sclerosis (MS) or experimental autoimmune encephalomyelitis (EAE), is an 
attractive modality [13, 14].  In MS and EAE, autoreactive T cells specific for myelin 
antigens play an important role in pathogenesis.  Immunization with myelin-basic 
protein-reactive T cells induces an anti-idiotypic CD8+ cytolytic T cell response [14], as 
well as CD4+ regulatory T cell responses [15], and, to a lesser extent, humoral responses 
[16].  Based on the results of successful TCV in animal models, clinical trials in a small 
number of MS patients have been initiated [17].  
     In the present study, using autoreactive CD4+V8.3 Th1 clones, which we isolated 
from splenocytes of lupus-prone MRL/lpr mice, the impact of variables regulating TCV 
success in this animal model was investigated.    
52. Materials and Methods
2.1. Mice
MRL/MpJ Jms Slc-Faslpr/lpr mice (MRL/lpr mice) were purchased from the Sankyo Lab 
service Corp. (Shizuoka, Japan).  These mice were bred and housed in specific 
pathogen-free facilities at the Graduate School of Medicine, Kyoto University.  The 
Kyoto University Animal Welfare Committee approved all procedures (approval number 
Med Kyo 07073).   
2.2. Generation of autoreactive Th clones from lymphocytes of antinuclear Ab-positive 
MRL/lpr mice
Autoreactive Th clones were isolated and cloned according to Naiki’s method with some 
modifications [18].  Briefly, a single cell suspension of lymph node cells was prepared 
from anti-dsDNA Ab- or anti-U1-ribonucleoprotein (U1RNP) Ab-positive MRL/lpr mice 
(age = 3-4 months).  The cells were treated with red blood cell lysis buffer (Sigma 
Chemical Co., St. Louis, MO).  Initially, 4 x 106/ml cells were cultured in 24-well tissue 
culture plates with Click’s medium (Irvine Scientific, Santa Ana, CA) supplemented with 
10% fetal calf serum, antibiotics, L-glutamine, and 2-mercaptoehtanol.  2 x 106/ml 
irradiated (30 Gy) syngeneic splenocytes as antigen presenting cells (APCs) were added 
weekly along with 10 units/ml mouse rIL-2 (R&D systems, Minneapolis, MN) in the 
absence of foreign antigens.  After 1 month, cells were transferred at limiting dilution to
96-well plates at a concentration of 0.5 cells/well.  Growing cells (< 5/plate) were then
harvested and further expanded in 24-well plates.  
2.3. Cytokine ELISA
6The isolated Th clones (2 x 105/well) were stimulated for 24 or 48 h by plate-bound 
anti-CD3 mAb (5 g/ml, 500A2, Becton Dickinson, San Jose, CA) in 48-well plate.  
Concentrations of IFN and IL-4 in culture supernatants were measured by ELISA 
according to manufacturer’s protocol (Becton Dickinson).  All samples were performed 
in duplicate.
2.4. Flow cytofluorometric analysis  
Th clones were analyzed by flow cytometry, using anti-TCR-C (H57-597-PE, Becton 
Dickinson), anti-CD4 (H129.19-FITC), anti-CD3 (500A2-PE), and anti-B220 
(RA3-6B2-FITC) monoclonal antibodies (mAbs).  For the determination of the TCR V
region, mAb against V3 (KJ25-FITC), V4 (KT4-FITC), V6 (RR4-7-FITC), V7 
(TR310-FITC), V8 (F23.1-PE), V8.1/8.2 (MR5-2-FITC), V8.3 (1B3.3-FITC), V9 
(MR10-2-FITC), V10 (B21.5-FITC), V13 (MR12-3-FITC), V14 (14-2-FITC) and 
V17 (KJ23-FITC) were used.  Stained cells were analyzed by acquisition on a 
FACScan® flow cytometer (Becton Dickinson) and analyzed by CellQuestTM software 
(Becton Dickinson).
     For detection of Th clone-binding IgM and/or IgG Abs in sera from MRL/lpr mice, 
2 l of serum from each of 10 MRL/lpr mice, which received PBS, irradiated clone dna51 
(i-dna51) or irradiated clone rnp2 (i-rnp2) cells, was diluted in 180 l of PBS.  This 
mixture was incubated with the T cell clones for 30 min, and then FITC-conjugated goat
anti-mouse (IgM+IgG) Abs used as second Abs. For determination of IgG Abs against T 
cell clones, a 1:100 dilution of serum from some of the MRL/lpr mice, which received 
stimulated (s-) dna51 or i-dna51 cells, was incubated with the clones for 30 min, and then 
visualized with FITC-conjugated goat anti-mouse IgG Abs. 
72.5. RNA extraction and sequence analysis of the TCR-chain by reverse-transcription 
PCR
Monoclonality of T cells was confirmed by determination of T cell receptor (TCR) 
sequence.  Total RNA was extracted from the Th clone, and the TCR-chain V-D-J 
sequence was determined by reverse-transcription PCR.  Total RNA (5 g) was 
reverse-transcribed using AMV transcriptase.  The resulting cDNA was PCR-amplified 
through 40 cycles (94C, 1 min; 60C, 1 min; 72C, 4 min) using probes specific for 
V8.3 (CAT TAT TCA TAT GGT GCT GGC) and C(CTT GGG TGG AGT CAC ATT 
TCTC).  The amplified cDNA was sequenced directly with V8.3 primer and then 
matched using the international ImMunoGeneTics (IMGT) database [20].
2.6. Proliferation assays
For Th1 clone-mediated B cell proliferation assays, purified B cells (5 x 104/well) were 
co-cultured with irradiated (20 Gy) Th1 clone, dna51 (2 x 104 /well) in 200 l medium in 
triplicate using round bottom 96-well plate for 3 days.  B cells were purified from 
splenocytes of MRL/lpr mice by CellectTM Mouse B (Biotex Laboratories Inc., Edmonton, 
Canada) followed by further T cell depletion using anti-Thy1.2 antibody (HO-13-4) and 
Low-Tox-M rabbit complement (Accurate Chemical & Scientific Corporation, Westbury, 
NY; B cell purity >95% as determined by flow cytometry).  After 1 Ci of [3H]-labeled 
thymidine (Amersham, Arlington Heights, IL) was added during the last 16 h of culture, 
cells were harvested with a semi-automatic cell harvester (Skatron Instruments, Sterling, 
VA).  Incorporated radioactivity was measured using a -plate scintillation counter 
(Beckman Instruments, Fullerton, CA).  To examine the clone dna51-B cell cognate 
interaction, anti-CD40L mAbs (MR1, NA/LE, Becton Dickinson) or the isoptype control 
IgG was incubated in culture for 3 days. 
8     For Th clone proliferation assays in the presence of treated MRL/lpr mouse B cells, 
B cells were purified from splenocytes of Th clone-vaccinated MRL/lpr mice.  Purified 
B cells (1 x 105) were irradiated (30 Gy) and then co-cultured with Th clones (1 x 105) for 
3 days. After 1 Ci of [3H]-labeled thymidine was added during the last 16 h of culture, 
cells were harvested and incorporated radioactivity was measured.  For functional assay 
of anti-vaccinated clone Abs, proliferative response of the Th clone (1 x 105/well) in the 
presence of APCs (5 x 105 of irradiated MRL/lpr splenocytes) was examined with T cell 
vaccination (TCV)-treated MRL/lpr mouse sera (1:50 dilution).  In addition, to confirm 
whether anti-vaccinated clone Abs themselves in sera work or not, MRL/lpr mouse sera 
and dna51 V8.3-complementarity-determining region (CDR) 3 synthetic peptides 
(ASRETGGGDTQY, final concentration = 50 g/ml) were preincubated before 
proliferation assay. 
2.7. Antinuclear Ab detection by ELISA
Anti-dsDNA Abs were measured according to the method of Rubin [19].  For detection 
of anti-U1RNP Ab, the MESACUP-2 test® RNP (MBL Laboratories, Co., Nagoya, Japan) 
was used.  Mouse sera were diluted 1:100 with PBS containing 3% bovine serum 
albumin and incubated at room temperature for 2 h, followed by detection of bound IgG 
with alkaline phosphatase-conjugated anti-mouse IgG (Southern Biotechnology 
Associates Inc., Birmingham, AL) at OD405nm in a microtiter ELISA reader.  Using 
anti-dsDNA Ab- or anti-U1RNP Ab-positive (defined as 300 units) and negative (0 units)
standard mouse serum (1:100 dilution), arbitrary units of experimental Ab titer in sample
were calculated.  In case of MRL/lpr mouse sera, arbitrary units of Abs were calculated 
as ([OD405nm of experimental serum - OD405nm of negative standard] x300 / [OD405nm of 
positive standard - OD405nm of negative standard]).  In in vitro helper assay supernatant, 
9arbitrary units of Abs were calculated as ([OD405nm of experimental wells – OD405nm of no 
cell wells (background)] x300 / [OD405nm of positive standard - OD405nm of negative 
standard]).
     
2.8. In vitro helper assay
Th cells (5 x 105/well) were co-cultured with 2 x 106 of purified MRL/lpr B cells in 
24-well plates for one week.  Culture supernatants were harvested and arbitrary units of 
anti-dsDNA and anti-U1RNP Abs were determined by ELISA (Refer to Antinuclear Ab 
detection by ELISA).  Next, stimulation index was calculated as (Ab arbitrary units of 
[Th clone+B cells] / Ab arbitrary units of [B cells alone well]).  For examining cell 
contact-dependent Ab production, Th clones (5 x 105/well, upper the membrane) and 
purified MRL/lpr B cells (2 x 106/well, lower the membrane) were placed separately using
a 10m thin transparent polycarbonate membrane insert (0.4 m pore size, 
Becton-Dickinson Labware, Mountain View, CA) in 24-well plate and incubated for one 
week.  Then, membrane insert was removed and supernatant was mixed.  Anti-nuclear 
Ab arbitrary units in supernatant were determined by ELISA and stimulation index was 
calculated as above.
2.9. Adoptive transfer study with Th1 clones
As controls, stimulated Th1 clones dna51 and rnp2 (1-2 x 106 cells) by rIL-2 (10 units/ml 
for 24 h) (designated as s-dna51 or s-rnp2) were transferred intravenously into each 
MRL/lpr mouse (10 mice in each group receiving Th1 clones).  Cultured Th1 clones 
were stained by trypan blue and more than 95% of non-staining cells in culture were 
confirmed before transfer. To completely remove APC contamination, cells were used at 
least 2 weeks after the last addition of APCs.  The purity of the transferred cells was 
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>98% as determined by flow cytometric analysis.  For vaccination, the same amount of 
stimulated Th1 clones was irradiated (20 Gy) before transfer (10 mice in each group 
receiving Th clones [designated as i-dna51 or i-rnp2]).  From the 1st transfer into mice 3 
weeks of age, transfers were performed intravenously every three weeks (total of 6 
transfers).  Serum samples were collected periodically for examining urinary protein 
amount, serum creatinine level, and anti-nuclear Ab titers. All mice were sacrificed and 
skin, lungs, and kidneys were collected for histological evaluation at 26 weeks of age.  
At the same time, splenocyte subpopulations were analyzed by flow cytometry and the 
groups compared. 
2.10. Morphometric analysis and immunohistochemistry
For light microscopy, sagittal kidney sections were fixed by immersion in Carnoy’s 
solution followed by 4% buffered formaldehyde and embedding in paraffin.  
One-micron-thick sections were stained with hematoxylin-eosin and periodic acid-Schiff.  
The renal activity index (AI) proposed by Austin et al. [21] was calculated. Briefly, the 
AI of glomerular abnormalities (cellular proliferation, fibrinoid necrosis/karyorrhexis, 
cellular crescents, hyaline thrombi/wire loop, and leukocyte infiltration) and 
tubulointerstitial abnormalities (mononuclear cell infiltration) were calculated separately.  
Additionally, the number of glomerular cells and the mesangial area were measured 
quantitatively with a computer-aided manipulator (KS400, Carl Zeiss Vision, Munich, 
Germany) by counting the nuclei and analyzing the periodic acid Schiff-positive area 
within the glomerular tuft.  More than 10 consecutive glomerular sections, randomly 
selected in each mouse by scanning from the outer cortex, were examined without 
knowledge of the origin of the slides, and the mean values were calculated [22].  For 
immunofluorescence of mouse C3, 1 m-thick cryostat sections were fixed in acetone.  
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The sections were washed with phosphate-buffered saline and incubated overnight at 4ºC 
with FITC-labeled goat anti-mouse C3 (ICN, Aurora, OH).  
     
2.11. Detection of Abs against dna51 V8.3-CDR3 peptides
Synthetic peptides (ASRETGGGDTQY) of dna51 V8.3-CDR3 with coating buffer 
(pH9.4) (10 g/ml) were bound to ELISA plates, and wells blocked by 5% bovine serum 
albumin in PBS.  1:100 diluted sera from MRL/lpr mice were incubated for 2 h at room 
temperature, followed by detection of bound IgG with alkaline phosphatase-conjugated 
anti-mouse IgG at OD405nm in a microtiter ELISA reader.  All assays were performed in 
triplicate.
     
2.12. Cytotoxicity assays
Cytotoxicity of CD4+ and CD8+ T cells derived from vaccinated MRL/lpr mouse 
splenocytes against dna51 was determined by Cytotox 96® (Promega Corp., Madison, WI) 
according to the manufacturer’s protocol.  CD4+ or CD8+ T cells (effector cells, 2.5-40 
x104 /well) purified using a MACS® isolation kit (Miltenyi Biotec, Inc., Auburn, CA) and 
dna51 (target cells, 2x104 /well) were incubated in a round-bottom 96-well culture plate 
for 4 h (experimental wells).  Control wells for effector or target cell spontaneous LDH 
release were set up, and the maximum LDH release control wells of target cells were 
made.  Then, LDH release in supernatant of experimental wells was determined.  The 
percent specific cytolysis was calculated as ([experimental - effector spontaneous - target 
spontaneous] / [target maximum - target spontaneous]) x100.
2.13. Statistical analysis
Mortality curves were plotted using the Kaplan-Meier method and significance estimated 
12
using the Mantel-Cox log-rank test.  For other statistical tests, the nonparametric 
Mann-Whitney rank sum test or Wilcoxon signed rank sum test were used. 
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3. Results
3.1. Characterization of the isolated clones dna51 and rnp2
For the present study, two Th clones, rnp2 and dna51, expressing the TCR, CD4, and 
CD3, but not B220 (data not shown) were selected from the isolated 26 clones.  Both 
secreted IFN, but not IL-4, indicating that they are Th1 clones (Fig.1A).  In vitro helper 
assays demonstrated that clone dna51 augmented the production of anti-dsDNA and clone 
rnp2 the production of anti-U1RNP Abs (Fig. 1B).  Ab secretion was T-B 
contact-dependent and syngeneic B cell proliferation was mediated by CD40-CD40L 
costimulation (Fig.1B, C). Screening with mAbs to each VTCR indicated the presence 
of V14 and V8.3 on clones rnp2 and dna51, respectively.  cDNA of the dna51 
TCR-chain was a 210 base-pair fragment, and V8.3 and J2.6 usage was confirmed by 
reference to the international ImMunoGeneTics database [20].  The amino acid sequence 
of the dna51TCR junctional region was ASRETGGGDTQY (AGC AGG GAG ACA 
GGG GGC GGA GAC ACC CAG).  
3.2. The effect of T cell vaccination (TCV)
Anti-dsDNA Ab production was suppressed in 18 and 24 week-old MRL/lpr mice 
receiving irradiated (i-) dna51 cells (Fig. 2A).  MRL/lpr mice that received stimulated 
(s-) dna51, s-rnp2 or i-rnp2 had titers of anti-dsDNA Abs equal to the PBS-treated animals.  
Anti-U1RNP Ab secretion was stimulated in MRL/lpr mice that had received s-rnp2 and 
s-dna51 cells compared to PBS-treated controls (Fig. 2B).  This result is consistent with a 
previous report of CD40L-independent anti-U1RNP Ab stimulation [23].
     Compared to PBS-treated animals (Fig. 3A, F), glomerular cell infiltration, activity 
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index (AI) in glomerular lesions, and immune complex deposition were all suppressed in 
MRL/lpr mice receiving i-dna51 (Fig. 3C, H, and Table 1).  Those receiving s-dna51 
suffered greater glomerular cell infiltration, increased mesangial areas and higher AI than 
PBS-treated MRL/lpr mice (Table 1).  MRL/lpr mice receiving s-dna51 had higher total 
and glomerular AI than s-rnp2 recipients, but the latter tended to manifest higher AI of 
tubulointerstitial abnormalities than PBS-treated controls (Table 1).  Other organs such as 
skin and lungs suffered damage to a similar extent as the vaccinated and PBS-treated 
MRL/lpr mice (data not shown).  
     Renal insufficiency was prevented in the i-dna51-vaccinated MRL/lpr mice
compared to the other groups at 24 weeks (Table 1).  Proteinuria at 24 weeks was 
observed in all the groups and there was no statistically significant difference of protein 
amounts measured semiquantitatively by a test paper (Terumo Co., Tokyo, Japan) among 
5 groups (data not shown).  Significant differences in survival rates between clone 
recipients and PBS-treated MRL/lpr mice were not observed until 23 weeks (Fig.4).  
3.3. Altered splenocyte subpopulations in the vaccinated MRL/lpr mice
To elucidate mechanisms responsible for TCV-mediated protection in MRL/lpr mice, the 
numbers of total splenocytes, T cell subsets (CD4+CD8-, CD4+CD8+, CD4-CD8- [double 
negative], CD4+V8.3+, CD4+V14+), and CD3-B220+B cells were calculated using flow 
cytometry at 26 weeks.  The numbers of CD4+V8.3+T cells were decreased in MRL/lpr 
mice receiving i-dna51 cells (Fig. 5A).  In i-rnp2 recipients, CD4+V14+ T cells tended 
to be fewer in number than in PBS-treated MRL/lpr mice (data not shown).  While total 
numbers of T cells (including CD4+CD8-, CD4+CD8+ and double-negative T cells) were
not decreased (data not shown), there were fewer B cells in i-dna51 and i-rnp2-recipients
than PBS-treated MRL/lpr mice (Fig. 5A).  Irradiated B cells from i-dna51 recipients
15
failed to stimulate dna51 proliferation, whereas irradiated B cells from i-rnp2 recipient 
MRL/lpr mice could enhance dna51 proliferation (Fig. 5B).  Thus, B cell function as 
APC for dna51 appears to be more downregulated in i-dna51 recipients than in i-rnp2 
recipients, probably because the percentage of B cells, which can stimulate proliferation of 
dna51, among total splenic B cells is reduced in i-dna51 recipients. 
3.4. Generation of Abs against the T cell clones used to vaccinate the MRL/lpr mice
Sera from i-dna51 recipients contained Ig against the dna51 T cell clone (Fig. 6A).  Thus, 
Ig in sera from i-dna51 recipients strongly reacted with clone dna51 cells, but not with the 
CD4+V14+Th1 clone rnp2 (Fig. 6B). Sera from non-autoimmune normal B10.BR/SgSn 
Slc mice reacted with neither clones (data not shown). Anti-dna51 Abs were present in 
sera from both i-dna51 and s-dna51 recipients (Fig.6C).  To investigate whether 
anti-dna51 Abs recognize the CDR3 region, we established an ELISA system with 
synthetic peptides corresponding to the dna51 V8.3-CDR3 region (ASRETGGGDTQY).  
Anti-[dna51 V8.3-CDR3] Ab titers were significantly higher in sera from mice receiving 
the s-dna51 or i-dna51 vaccine than in i-rnp2 or s-rnp2 recipients, or PBS-treated controls
(Fig. 7A). Anti-dna51 Abs in the s- and i-dna51 recipients were found to have inhibitory 
effects on dna51 cell proliferation (Fig. 7B), and synthetic peptides (ASRETGGGDTQY)
reversed the inhibitory effect of dna51 proliferation by anti-dna51 Ab-containing sera (Fig. 
7B).  
3.5. Cytotoxicity against dna51 mediated by T cells purified from splenocytes of 
vaccinated MRL/lpr mice
To determine anti-clonotypic T cells in TCV-treated MRL/lpr mice, LDH release assay 
was performed.  CD8+ T cells from i-dna51 recipients lysed dna51 used as the vaccine at
16
lower effector/target cell (E/T) ratios (>=2.5).  CD4+ T cells from i-dna51 recipients 
exerted cytotoxicity against dna51 cells only at the highest E/T ratio tested (=20).  Both 
CD4+ and CD8+ T cells derived from i-rnp2 recipients had little killing effects on dna51.  
17
4. Discussion
In the present study, adoptive transfer of an irradiated CD4+V8.3+Th1 clone (T cell 
vaccination, TCV) was shown to decrease activity of IC-mediated glomerulonephritis and 
regulate anti-DNA Ab production in MRL/lpr mice.  Our isolated clone, dna51, were 
thought to be autoreactive, because dna51 survived and proliferated without no exogenous 
antigens (Fig.7B) and stimulated syngeneic B cells to secrete anti-dsDNA Abs by cognate 
interaction (Fig.1B, C). This is the first report of vaccination with anti-dsDNA 
Ab-stimulating autoreactive Th1 clone.  Because Th1-predominancy in MRL/lpr mice 
has been repeatedly confirmed [24, 25] and because nucleosome-reactive human T cells 
produce substantial quantities of IFN [11], TCV using autoreactive Th1 cells may be 
more effective than using Th2 cells.  While anti-dna51 TCR-CDR3 Ab production was 
augmented by adoptive transfer of s-dna51 as well as i-dna51 cells, the number of
CD4+V8.3+ T cells was not decreased and renal disease was not ameliorated in MRL/lpr 
mice receiving s-dna51, s-rnp2, or i-rnp2 cells. Thus, unirradiated clone dna51, or clone 
rnp2 with or without irradiation, are not effective for TCV in MRL/lpr mice.  On the 
other hand, significantly improved survival and proteinuria of TCV-treated animals were 
not confirmed for any group.  The explanations for this may be 1) TCV effects with a 
single clone was limited, and 2) other MRL/lpr diseases such as interstitial pneumonia and 
severe skin disease [26] were found not to be completely suppressed by TCV with 
i-dna51.
     In the present study, TCV in MRL/lpr mice induced 1) clonal depletion of 
nephritogenic CD4+V8.3+ T cells, 2) suppression of circulating anti-dsDNA Ab 
associated with IC-mediated nephritis, and 3) decreased number of B cells as well as 
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CD4+V8.3+ T cells.  Thus far, only TCV studies using polyclonal autologous 
lymphocytes against murine and human lupus antigens have been reported.  De Alborán 
et al. used CD3+CD4-CD8- (double negative) lpr T cells for vaccination of MRL/lpr mice 
[27].  Because the number of V8.2+ T cells was significantly decreased in these 
vaccinated MRL/lpr mice, V8.2+ T cell involvement in the disease-preventing 
mechanism was suggested.  Ben-Yehuda et al. adoptively transferred spleen cells from 
MRL/+ mice vaccinated with MRL/lpr lymphocytes and reported that production of 
anti-DNA Abs and glomerulonephritis could be prevented by such “MRL/+-derived 
protective T cells” that might have been responding to at least one antigen on the MRL/lpr
cells [28].  Although these previous results showed the importance of a certain 
lymphocyte subset including T cells both in MRL/lpr disease and immunoregulatory 
mechanisms for TCV, the vaccinate T cells in earlier studies were not well characterized 
and not clinically applicable for human lupus.  Recently, autologous TCV has been tested 
in Chinese patients with SLE [29].  Purified CD4+ T cells from PBMC were injected 
after 25Gy irradiation, and clinical improvements together with decreased titers of 
antinuclear Abs in most patients were reported. Efficacy in that study was shown only 
for mild lupus manifestations, which can easily be treated with low dose corticosteroid 
and/or conventional immunosuppressants.  TCV with unselected T cells is therefore a 
questionable therapeutic approach in intractable lupus manifestations, such as lupus 
nephritis.  These therapeutic trials, however, are encouraging and oligoclonal T cells and 
TCR peptide-based immunotherapy has shown some potential efficacy in MS [30].  
     Anti-idiotypic Abs against dna51 had suppressive effects on the clone dna51 in vitro.  
These immunoregulatory Abs recognized the V CDR3 of dna51, and T-B cognate help 
for anti-dsDNA Ab production might thus be inhibited.  Monoclonal anti-dna51 Abs
could therefore represent therapeutic agents in lupus-prone mice.  It was noteworthy that 
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the number of B cells was also decreased in MRL/lpr mice receiving i-dna51.  B cells 
from these i-dna51-vaccinated MRL/lpr mice failed to stimulate proliferation of dna51, 
perhaps because autoantigen-presenting B cell lysis might have occurred in vivo.  We 
previously cloned a T cell line that down-regulates anti-dsDNA Ab production [31].  
One line, GD12, killed activated MRL/lpr B cells, an effect dependent on TNF-TNF-R1 
interactions.  Killing by GD12 required cognate interaction between the B cell targets 
and the T cells.  Although TCV failed to increase T cell numbers, a certain subset of 
T cells such as represented by GD12 might be induced by the administration of 
autoreactive Th1 clones and be responsible for some of the phenomena observed here.  
     The importance of T cells in lupus has been confirmed by experiments in which 
thymectomy prevented disease in MRL/lpr mice [32, 33].  The clinical utility of 
autoreactive T cell-targeting treatments in other lupus-prone mice has been repeatedly 
demonstrated.  Diseased (wild-type) MRL/lpr mice spontaneously have T cells 
resembling dna51 (Fig. 6A).  In SNF1 mice, histone autoepitopes for nephritogenic 
autoantibody-producing T cells were identified [34], and their administration shown to 
delay the onset of severe lupus nephritis in prenephritic mice and to prolong survival and 
halt the progression of glomerulonephritis even in mice with established lupus nephritis 
[35].  Also, low-dose nucleosomal peptides have been reported to downregulate murine 
lupus [36].  Hahn et al. synthesized a peptide based on T cell stimulatory sequences from 
the VH regions of murine anti-DNA Abs (pCONS), which could induce immune tolerance 
in BWF1 mice [37].  Further, Ferrera et al. showed that treatment by pCONS induced 
TGF-producing CD8+CD28-T cells, which suppressed the antigen-specific stimulation of 
CD4+ T cells and reduced Ab production [38].  The success of such strategies implies
that the repertoire of antigen receptors expressed by autoreactive cells is oligoclonal or 
restricted.  Fujio et al. indicated that TCR and CTLA-4Ig gene-transfected
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nucleosome-specific T cells could suppress murine lupus nephritis, strongly suggesting 
that autoantigen hyperpresentation by antigen-presenting cells contributes to the 
propagation of lupus [39].  The previous studies clearly demonstrated that lupus nephritis
mediated by a particular T cell population could be prevented or reversed by regulatory 
Abs and/or T cells recognizing the TCR expressed on the pathogenic T cells. 
      There is evidence that myelin basic protein (MBP)-reactive T cells undergo in vivo
activation and accumulate in the brain of MS patients.  The results of preliminary clinical 
trials confirm that TCV depletes circulating MBP-reactive T cells [17].  The previous 
reports demonstrated several regulatory mechanisms of TCV [14-16, 40-42].  An
anti-idiotypic T cell response, predominantly by CD8+ cytotoxic T cells, which recognize 
the immunizing T cell clones, is clearly involved in autoreactive T cell depletion.  In 
EAE, CD8+ T cell-mediated cytotoxicity appeared to be more important than Abs against 
the MBP-specific T cells [14], while anti-idiotypic humoral responses as well as 
anti-idiotypic cellular responses were induced [16, 40].  Our data suggests that 
anti-clonotypic CD8+ T cells are induced by TCV also in MRL/lpr mice.  While CD4+ T 
cells appeared to have cytotoxic effects against dna51, a potential physiological effect of 
CD4+ T cells might be different from that of CD8+ T cells.  To answer the important 
point, which subset of CD4+ T cells proliferates in response to dna51 should be examined.  
Because CD4+ Th1 cells from i-rnp2-received MRL/lpr mice appeared not to be effective, 
anti-ergotypic T cell response [42], which recognizes non-specific activated T cells, may 
be different from CD4+ T cell-mediated cytotoxicity in the present study.  Rather, CD4+
T cells from i-dna51-received MRL/lpr mice may include CD4+CD25+Treg, which were 
anti-idiotypic T cells against CDR2 [43].  Alternatively, CD4+T cells expressing 
V1V1 may be involved [44].  Why higher effector/target ratio was required for CD4+T 
cell-mediated dna51 cytolysis is due to the small number or low cytotoxicity of 
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anti-CDR2 CD4+CD25+Treg and CD4+T cells in splenic CD4+T cells.  To establish the
role of an anti-ergotypic T cell response, cytokine secretion from CD4+T cells in our 
TCV-treated MRL/lpr mice also needs to be determined, whereas IL-10 plays a 
pathogenic role in SLE [45].      
     In lupus, it is proposed that oligoclonal T cell subsets are involved in the 
pathogenesis of nephritis [4, 46].  It remains to be determined whether the deletion of a 
single clone is sufficient to account for clinical efficacy, because TCR of pathogenic 
autoreactive T cells from individuals with lupus can recognize more than one nucleosomal 
peptide epitope [34, 35] in the context of diverse MHC class II molecules.  We believe 
that TCV with a single clone can elicit anti-ergotypic as well as anti-idiotypic response 
and Cohen et al. reported the beneficial effects of a single clone vaccination on adjuvant 
arthritis [47].  In MS, however, anti-clonotypic T cell responses induced by oligoclonal 
TCV are restricted to the vaccinated clone and cannot affect the other MBP-reactive 
clones not used for vaccination [48].  Of interest, in patients with clinical exacerbation, 
MBP-reactive T cells, which were originate from clonal origin different from those of T 
cells persisting before oligoclonal TCV, reappeared [48].  These results indicate that 
depletion of autoreactive T cell clones causes a shift in the T cell repertoire.  Taken 
together, also in MRL/lpr mice or lupus, TCV with as many pathogenic Th clones as 
possible is supposed to be more effective than TCV with a single clone. 
     In conclusion, TCV induced both regulatory Abs and cytotoxic CD8+T cells against 
the vaccinate cells and decreased the activity of MRL/lpr lupus nephritis, while the effect 
with a single clone may be limited.  Whereas more extensive knowledge on the detailed 
regulatory mechanisms remains to be determined, TCV may have potential for 
suppressing autoreactive T cell targets and altering anti-dsDNA Ab production.   
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Fig. 1.  Characterization of the isolated Th1 clones by in vitro helper assay
A. The isolated Th clones (dna51 and rnp2) secrete IFN but not IL-4 by plate-bound 
anti-CD3 mAb-stimulation.  
B. Anti-dsDNA Ab and U1RNP Ab in the culture supernatant of each clone (dna51, or 
rnp2) and purified MRL/lpr B cells were shown.  In the absence of a 10m thin 
transparent polycarbonate membrane insert (M-), the clones dna51 and rnp2 induced 
anti-dsDNA and anti-U1RNP Abs, respectively.  The autoantibody production is 
inhibited by a membrane insert between T (upper) and B (lower) cells (M+).  In the 
experiment, from OD405nm measured by ELISA, arbitrary units of autoantibodies in 
supernatants were calculated as ([experimental wells – no cell wells (background)] 
x300 / [Ab-positive standard mouse serum - Ab-negative standard mouse serum]).  
Experimental wells include Th clones+B, and B cells alone wells in in vitro helper 
assay.  OD405nm of anti-dsDNA and U1RNP Ab-positive standard mouse serum was 
2.120 and 1.891, respectively, as 300 units.  OD405nm of negative standard normal 
mouse serum is 0.106 as 0 units.  OD405nm of no cell wells (background) was 0.086 
and subtracted from OD405nm of experimental wells.  Stimulation index was 
calculated as (anti-dsDNA Ab arbitrary units of [Th clone+B cells] / anti-dsDNA Ab 
arbitrary units of [B cells alone well]).  Data are representative of three independent 
experiments with similar results.
C. Proliferation of purified MRL/lpr B cells in the presence of irradiated dna51 with 
anti-CD40L mAb (MR1) or isotype control (hamster IgG) was shown.  Proliferation 
of B cells alone was 1045 cpm.  
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Fig. 2.  Anti-dsDNA and U1RNP Ab kinetics in sera from vaccinated MRL/lpr mice
A. Stimulated (s-) dna51 (n= 7), s-rnp2 (n= 9), and irradiated (i-) rnp2 (n= 9) recipients 
have identical titers of anti-dsDNA Abs in comparison with PBS-treated controls at the 
last observation.  At 18 and 24 weeks of age, anti-dsDNA Ab titer in the 
i-dna51-recipients (n= 10) is significantly lower than the PBS-treated (vehicle) controls 
(n= 9).  
B. Anti-U1RNP Ab production in the vaccinated or PBS-treated MRL/lpr mice. s-dna51 
and s-rnp2, but not i-dna51 and i-rnp2, recipients have more increased titers of 
anti-U1RNP Abs in comparison with PBS-treated controls.  
*P<0.05, **P<0.01 (compared with PBS-treated MRL/lpr mice)
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Fig. 3.  Renal histology and immunofluorescence study in vaccinated MRL/lpr mice  
Representative results of hematoxylin-eosin (A-E) and immunofluorescence (mouse 
complement, C3) (F-J) of glomeruli from 26 week-old MRL/lpr mice (magnification = 
x200). A, F. PBS-treated MRL/lpr mice (vehicle) developed immune-complex-mediated 
lupus nephritis.  B, G. Marked glomerular cell infiltration is observed in stimulated (s-) 
dna51 recipients.  C, H. Decreased numbers of glomerular–infiltrating cells and reduced 
linear deposition of immune complexes can be seen in irradiated (i-) dna51 recipients.  D, 
I. In addition to glomerular cell infiltration, tubulointerstitial inflammation is noted in 
some s-rnp2 recipients.  E, J. Glomerular cell infiltration is seen in i-rnp2 recipients as 
well as PBS-treated MRL/lpr mice. 
Fig. 4.  Survival rate of MRL/lpr mice treated with TCV.  
There is no statistical difference among the 5 groups until 23 weeks.  Treated animal 
numbers were shown in parenthesis.  
PBS= PBS-treated MRL/lpr mice, s-rnp2= s-rnp2-received MRL/lpr mice, s-dna51= 
s-dna51-received MRL/lpr mice, i-rnp2= i-rnp2-received MRL/lpr mice, i-dna51= 
i-dna51-received MRL/lpr mice
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Fig. 5.  Flow cytometric analyses and B cell dysfunction of splenocytes from
vaccinated MRL/lpr mice 
A. CD4+V8.3+T cell number in the spleen is decreased in the 26 week-old i-dna51 
recipients. Numbers of CD3-B220+B cells in splenocytes are significantly decreased 
in the i-dna51 and i-rnp2 recipient MRL/lpr mice.  *P<0.05 (compared with 
PBS-treated MRL/lpr mice)
B. B cell function as APCs derived from TCV-treated MRL/lpr mice is shown.  
Proliferative response of dna51 was significantly decreased when co-cultured with 
irradiated B cells (irrB) from i-dna51 recipients compared with when with irrB from 
i-rnp2.  *P<0.01
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Fig. 6.  Detection of Abs against Th1 clones in sera from the vaccinated MRL/lpr
mice  
A. Two microliters of serum from each of 10 i-dna51-recipients were diluted in 180 l of 
PBS.  This reacted strongly with the V8.3+ clone, dna51, used as the vaccine.  The 
same serum derived from the i-dna51-received MRL/lpr mice reacted with small 
number of V8.3+ MRL/lpr splenocytes (upper right).    
B. Diluted serum from i-dna51-recipients (red, n=10), but not from PBS-treated mice 
(blue, n=10), contains IgM and/or IgG reacting with clone dna51, used for vaccination.  
Serum from i-rnp2 recipient MRL/lpr mice (yellow, n=10) failed to react with dna51 
cells.  The mean fluorescent intensity (MFI) is shown in each histogram.
C. Reactivities with clone dna51 of representative sera from three s-dna51 (s-dna51- 1-3) 
and three i-dna51 (i-dna51- 1-3) recipients.  Both s-dna51 and i-dna51 recipient 
MRL/lpr sera contained IgG Abs against dna51 cells.  PBS-treated = Serum from 
PBS-treated MRL/lpr mouse (vehicle).  
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Fig. 7.  ELISA and proliferation study using synthetic peptides identical to the 
dna51 V8.3-CDR3 region 
A. Anti-[dna51 V8.3-CDR3 (ASRETGGGDTQY)] Ab titers are significantly higher in 
sera from s-dna51 and i-dna51 recipients than s-rnp2, i-rnp2 recipients, and
PBS-treated MRL/lpr mice after 18 weeks.  
*P<0.05, **P<0.01 (compared with PBS-treated MRL/lpr mice).  
B. Inhibitory effects of TCV-treated MRL/lpr mouse sera on dna51 proliferation are 
shown.  Anti-dna51 Ab-positive sera from s- and i-dna51 recipients, but not 
anti-rnp2 Ab-positive sera from s- and i-rnp2 recipients, decreased proliferation of 
dna51 cells in the presence of APCs.  Preincubation of the clone dna51-derived 
V8.3-CDR3 synthetic peptides (ASRETGGGDTQY, final concentration = 50 g/ml)
and anti-dna51 Ab-positive sera (50 l of 1:50 dilution) abrogated the suppression of 
dna51 cell proliferation.  
*P<0.05, **P<0.01 (between the indicated groups); (#)P<0.05 (compared with dna51 
proliferation in the presence of serum from PBS-treated MRL/lpr mouse)  
Fig. 8.  Cytotoxicity against dna51 mediated by purified T cells
LDH release assay shows that CD8+ T cells purified from i-dna51 recipient at an E/T ratio 
of 2.5, but not from i-rnp2 recipient MRL/lpr mouse splenocytes, kill dna51 cells.  At the 
highest E/T ratio (=20), CD4+ T cells from i-dna51 recipient MRL/lpr mice also lyse 
dna51.  Data are representative of three independent experiments with similar results.
Table 1. Renal pathological changes and serum creatinine in the vaccinated MRL/lpr mice
Activity index Glomerular cell Mesangial Serum
total glomerular  tubulointerstitial number (/glm) area (mm2/glm) creatinine (mg/dl)
PBS-treated 7.6±1.3 5.9±0.8 1.7±1.0 34.4±5.7 953±147 0.168±0.036
(n= 9)
s-dna51 10.3±2.3* 8.2±1.9* 2.1±0.3 46.0±9.3* 1124±49* 0.173±0.037
(n= 7)
i-dna51 3.2±1.7* 1.5±0.4** 1.7±0.8 25.7±3.4* 847±143 0.120±0.032*
(n= 10)
s-rnp2 7.0±1.6 3.9±1.2 3.1±0.5 30.1±6.2 871±155 0.182±0.111
(n= 9)
i-rnp2 7.3±2.0 4.8±1.6 2.5±1.0 31.3±2.4 884±66 0.157±0.041
(n= 9)
*P<0.05, **P<0.01 (compared with PBS-treated MRL/lpr mice)
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